3 completed, 3 withdrawn, 2 unknown, 1 active not recruiting. 6 Phase 2, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Hepatomegaly: new trials by email Literature Review of Hepatomegaly trials Research Report on Hepatomegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine - Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly | Not applicable | Recruiting | Phenomen Pharma | 90 | 2025-06-19 | 2025-07-23 |
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders Ruxolitinib - BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells | Phase 2 | Active not recruiting | Stanford University | 8 | 2019-11-15 | 2026-09-01 |
| Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus Hepatomegaly | Unknown | Assiut University | 60 | 2019-01-01 | 2018-09-11 | |
| Biomarker for Gaucher Disease: BioGaucher (BioGaucher) Splenomegaly, Hepatomegaly | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| Biomarker for Farber Disease (BioFarber) Farber's Lipogranulomatosis, Ceramidase Deficiency | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| Biomarker for Sly Disease (MPS VII) (BioSly) Developmental Delay, Skeletal Abnormalities | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis Isatuximab, Laboratory Biomarker Analysis - Amorphous, Eosinophilic, and Acellular Deposit, Constipation | Phase 2 | Completed | SWOG Cancer Research Network | 43 | 2018-06-06 | 2025-09-09 |
| Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment - Hepatomegaly, Myelofibrosis Transformation in Essential Thrombocythemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 8 | 2015-05-14 | 2019-05-15 |
| Open-Label Extension of LOCKCYST Trial lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Unknown | Radboud University Medical Center | 54 | 2008-04-01 | 2008-11-13 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| Octreotide in Severe Polycystic Liver Disease Octreotide, Placebo - Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease | Phase 2 / Phase 3 | Completed | Mayo Clinic | 42 | 2007-01-01 | 2012-11-21 |
| Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease Plant cell expressed recombinant glucocerebrosidase (prGCD) - Gaucher Disease | No longer available | Pfizer | 2018-09-07 |
Splenomegaly (6) · Liver Diseases (4) · Polycystic liver disease (3) · Gaucher Disease (2) · Polycystic Kidney Diseases (2) · Polycystic Kidney, Autosomal Dominant (2) · Abdominal Pain (1) · Anemia (1) · Constipation (1) · Diarrhea (1) · Eosinophilia (1) · Erdheim-Chester Disease (1) · Farber Lipogranulomatosis (1) · Fatty Liver (1)
Digestive System Diseases (12) · Hypertrophy (12) · Pathological Conditions, Anatomical (12) · Pathological Conditions, Signs and Symptoms (12) · Liver Diseases (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hemic and Lymphatic Diseases (5) · Metabolic Diseases (5) · Nutritional and Metabolic Diseases (5) · Hematologic Diseases (4) · Metabolism, Inborn Errors (4) · Nervous System Diseases (4) · Abnormalities, Multiple (3) · Brain Diseases (3)
lanreotide (2) · Nivolumab (1) · Octreotide (1) · S-Adenosylmethionine (1) · Ursodeoxycholic Acid (1) · isatuximab (1) · ruxolitinib (1) · taliglucerase alfa (1)
CENTOGENE GmbH Rostock (3) · Radboud University Medical Center (2) · Assiut University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Pfizer (1) · Phenomen Pharma (1) · SWOG Cancer Research Network (1) · Stanford University (1)
United States (5) · Egypt (3) · Germany (3) · India (3) · Belgium (2) · Netherlands (2) · Sri Lanka (2) · Israel (1) · Russia (1)
Peter Bauer, Prof. (3) · Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Emma Scott (1) · Joost PH Drenth, MD, PhD (1) · Joost PH Drenth, PhD (1) · Marie C. Hogan, M.D., Ph.D. (1) · Srdan Verstovsek (1) · William E Shomali, MD (1)
PMID 39356039, PMID 22773240, PMID 26166166, PMID 40925099
P30CA016672 (1), U10CA180888 (1), UL1RR024150 (1)